Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M25-059 Etentamig Platform Study in Multiple Myeloma
jRCT2051250078Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of etentamig in multiple myeloma (MM) (15 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicity of Etentamig + Daratumumab and Lenalidomide (DR), Dose-Limiting Toxicity of Etentamig Monotherapy as Maintenance and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051250078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250078.